Eli Lilly won regulatory approval for its rheumatoid arthritis drug Friday, nearly 14 months after the FDA rejected the once-daily pill due to safety concerns. But the approval comes with limitations that will likely hamper Lilly’s ambitions to turn the drug into a blockbuster seller.
The regulatory nod covers only the lower of the two doses of baricitinib (Olumiant) that Lilly (NYSE: LLY) hoped to bring to the market, which reduces the number of patients eligible for the new rheumatoid arthritis (RA) treatment. The drug’s label carries a black box warning-the FDA’s strictest notification of health risks associated with… Read more »
UNDERWRITERS AND PARTNERS